| Dr Ivan David Morrin, MD | |
|
210 Bevins Ln, Ste C, Georgetown, KY 40324-6120 | |
| (502) 868-0622 | |
| (502) 868-9097 |
| Full Name | Dr Ivan David Morrin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 210 Bevins Ln, Georgetown, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104825934 | NPI | - | NPPES |
| 64106701 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 39654 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Lexington, KY | Home health agency |
| Caretenders | Lexington, KY | Home health agency |
| Baptist Health Lexington | Lexington, KY | Hospital |
| Georgetown Community Hospital | Georgetown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
A new artificial joint restores important wrist-like movements to forearm amputees, something which could dramatically improve their quality of life.
Labopharm Inc. today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
› Verified 2 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
A new artificial joint restores important wrist-like movements to forearm amputees, something which could dramatically improve their quality of life.
Labopharm Inc. today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
› Verified 2 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518360296 PECOS PAC ID: 5597867184 Enrollment ID: O20150206000249 |
News Archive
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
A new artificial joint restores important wrist-like movements to forearm amputees, something which could dramatically improve their quality of life.
Labopharm Inc. today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ivan David Morrin, MD 210 Bevins Ln, Ste C, Georgetown, KY 40324-6120 Ph: (502) 868-0622 | Dr Ivan David Morrin, MD 210 Bevins Ln, Ste C, Georgetown, KY 40324-6120 Ph: (502) 868-0622 |
News Archive
Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
A new artificial joint restores important wrist-like movements to forearm amputees, something which could dramatically improve their quality of life.
Labopharm Inc. today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
› Verified 2 days ago
Dr. Gus A Bynum, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1154a Lexington Rd, Georgetown, KY 40324 Phone: 502-868-0008 | |
Makayla Ann Kiser, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 210 Bevins Ln, Suite C, Georgetown, KY 40324 Phone: 502-868-0622 Fax: 502-868-9097 | |
Mrs. Megan Elise Disponett-lee, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 106 Magnolia Dr Ste 200, Georgetown, KY 40324 Phone: 502-868-0806 | |
Raymond Wechman Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Rd, Ste 130, Georgetown, KY 40324 Phone: 502-867-0222 Fax: 502-867-0420 | |
Henry R Preston, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1138 Lexington Road Suite 130, Georgetown, KY 40324 Phone: 502-867-0222 Fax: 502-867-0420 | |
Nicholas Brett Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1502 Oxford Dr Ste 100, Georgetown, KY 40324 Phone: 502-570-3785 |